Two Sigma Investments
PCSA icon

Two Sigma Investments’s Processa Pharmaceuticals PCSA Stock Holding History

Two Sigma Investments’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-964
Closed -$57K – 3250
2024
Q1 		$57K Buy
964
+927
+2,505% +$73.4K ﹤0.01% 2877
2023
Q4 		$6.25K Buy
+37
New +$8.26K ﹤0.01% 3098

Other funds holding PCSA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MIM
Macroview Investment Management Bethesda, Maryland $144M AUM 19.29% 1-Year Est. Return

Two Sigma Investments's PCSA Position: Q2 2024 in Review

Two Sigma Investments sold out of Processa Pharmaceuticals (PCSA) in Q2 2024, closing a stake of 964 shares — an estimated $57K sold.

Two Sigma Investments first reported a position in PCSA in Q4 2023 and held it in 2 quarters. The position peaked at $57K in Q1 2024. 7 funds tracked by Wall St. Rank hold PCSA as of Q2 2024.

  • Two Sigma Investments reported no remaining Processa Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Two Sigma Investments sold 964 Processa Pharmaceuticals shares in Q2 2024, an estimated $57K.
  • Two Sigma Investments first reported a position in Processa Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Two Sigma Investments's Processa Pharmaceuticals position peaked at $57K in Q1 2024.
  • 7 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q2 2024.

Based on Two Sigma Investments's 13F filing for Q2 2024, filed 14 Aug 2024.